These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28294916)

  • 1. [New ral nticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
    Kazakov AI; Yashin S; Lyan EV; Ayrapetyan AV
    Kardiologiia; 2015 Aug; 55(8):30-34. PubMed ID: 28294916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
    Kazakov AI; Yashin SM; Lyan EV; Ayrapetyan AV
    Kardiologiia; 2015; 55(8):30-4. PubMed ID: 26761969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
    Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
    Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Improvements in oral anticoagulant therapy for atrial fibrillation].
    Briongos Figuero S; García Santos-Gallego C; Badimón JJ
    Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
    Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
    Hansen PS; Sanchez R; Walfridsson H
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.